GE to access bladder cancer imaging agent
This article was originally published in Clinica
Executive Summary
GE Healthcare has exercised an exclusive option in a previously-signed agreement with Norwegian company PhotoCure, granting the former rights to market in the US PhotoCure's Hexvix (hexaminolevulinate) optical molecular imaging agent. The product, used to diagnose and monitor bladder cancer, is currently under review by the FDA for market approval.